{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:04:59Z","timestamp":1789380299456,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"DOI":"10.1038\/s41371-026-01223-9","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:27:07Z","timestamp":1789378027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of telmisartan with losartan, valsartan, and candesartan on the risk of new-onset diabetes mellitus"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2336-0976","authenticated-orcid":false,"given":"Hyun-Wook","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3157-0247","authenticated-orcid":false,"given":"Hyejung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-5485","authenticated-orcid":false,"given":"Won-Woo","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeonghwan","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rae Woong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Youl","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Myung","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Gyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Won","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Jong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"1223_CR1","doi-asserted-by":"publisher","first-page":"205S","DOI":"10.1016\/S0895-7061(99)00103-X","volume":"12","author":"MR Weir","year":"1999","unstructured":"Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens. 1999;12:205S\u2013213S.","journal-title":"Am J Hypertens"},{"key":"1223_CR2","doi-asserted-by":"publisher","first-page":"3A","DOI":"10.1016\/S0002-9149(01)02321-9","volume":"89","author":"T Unger","year":"2002","unstructured":"Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89:3A\u20139A.","journal-title":"Am J Cardiol"},{"key":"1223_CR3","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-136-8-200204160-00010","volume":"136","author":"G Remuzzi","year":"2002","unstructured":"Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin\u2013angiotensin system inhibition. Ann Intern Med. 2002;136:604\u201315.","journal-title":"Ann Intern Med"},{"key":"1223_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/375247a0","volume":"375","author":"MB Marrero","year":"1995","unstructured":"Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P, et al. Direct stimulation of Jak\/STAT pathway by the angiotensin II AT1 receptor. Nature. 1995;375:247\u201350.","journal-title":"Nature"},{"key":"1223_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/bph.12159","volume":"169","author":"AC Sim\u00f5es e Silva","year":"2013","unstructured":"Sim\u00f5es e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol. 2013;169:477\u201392.","journal-title":"Br J Pharmacol"},{"key":"1223_CR6","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.1021\/jm049681p","volume":"47","author":"MC Breschi","year":"2004","unstructured":"Breschi MC, Calderone V, Digiacomo M, Martelli A, Martinotti E, Minutolo F, et al. NO-sartans: a new class of pharmacodynamic hybrids as cardiovascular drugs. J Med Chem. 2004;47:5597\u20135600.","journal-title":"J Med Chem"},{"key":"1223_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/164273","volume":"2008","author":"HA Pershadsingh","year":"2008","unstructured":"Pershadsingh HA, Moore DM. PPAR\u03b3 agonists: potential as therapeutics for neovascular retinopathies. PPAR Res. 2008;2008:164273.","journal-title":"PPAR Res"},{"key":"1223_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nm.3159","volume":"19","author":"M Ahmadian","year":"2013","unstructured":"Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPAR\u03b3 signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19:557\u201366.","journal-title":"Nat Med"},{"key":"1223_CR9","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.2337\/diabetes.50.9.2094","volume":"50","author":"N Maeda","year":"2001","unstructured":"Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPAR\u03b3 ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094\u20139.","journal-title":"Diabetes"},{"key":"1223_CR10","doi-asserted-by":"publisher","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","volume":"270","author":"JM Lehmann","year":"1995","unstructured":"Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3). J Biol Chem. 1995;270:12953\u20136.","journal-title":"J Biol Chem"},{"key":"1223_CR11","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","volume":"109","author":"M Schupp","year":"2004","unstructured":"Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-\u03b3 activity. Circulation. 2004;109:2054\u20137.","journal-title":"Circulation"},{"key":"1223_CR12","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.bbrc.2007.03.084","volume":"356","author":"A Moriuchi","year":"2007","unstructured":"Moriuchi A, Yamasaki H, Shimamura M, Kita A, Kuwahara H, Fujishima K, et al. Induction of human adiponectin gene transcription by telmisartan, angiotensin receptor blocker, independently on PPAR-\u03b3 activation. Biochem Biophys Res Commun. 2007;356:1024\u201330.","journal-title":"Biochem Biophys Res Commun"},{"key":"1223_CR13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","volume":"43","author":"SC Benson","year":"2004","unstructured":"Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR\u03b3-modulating activity. Hypertension. 2004;43:993\u20131002.","journal-title":"Hypertension"},{"key":"1223_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1291\/hypres.27.457","volume":"27","author":"G Derosa","year":"2004","unstructured":"Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res. 2004;27:457\u201364.","journal-title":"Hypertens Res"},{"key":"1223_CR15","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2169\/internalmedicine.46.7173","volume":"46","author":"Y Ichikawa","year":"2007","unstructured":"Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med. 2007;46:1331\u20136.","journal-title":"Intern Med"},{"key":"1223_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1475-2840-4-6","volume":"4","author":"C Vitale","year":"2005","unstructured":"Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 2005;4:6.","journal-title":"Cardiovasc Diabetol"},{"key":"1223_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12933-022-01524-6","volume":"21","author":"WW Seo","year":"2022","unstructured":"Seo WW, Seo SI, Kim Y, Yoo JJ, Shin WG, Kim J, et al. Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases. Cardiovasc Diabetol. 2022;21:82.","journal-title":"Cardiovasc Diabetol"},{"key":"1223_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5534\/wjmh.230327","volume":"43","author":"DY Yang","year":"2025","unstructured":"Yang DY, Seo WW, Park RW, Rhee SY, Cha JM, Hah YS, et al. Comparison of finasteride and dutasteride on risk of prostate cancer in patients with benign prostatic hyperplasia: a pooled analysis of 15 real-world databases. World J Mens Health. 2025;43:188\u201396.","journal-title":"World J Mens Health"},{"key":"1223_CR19","first-page":"1110","volume":"2","author":"R Makadia","year":"2014","unstructured":"Makadia R, Ryan PB. Transforming the Premier Perspective Hospital Database into the Observational Medical Outcomes Partnership (OMOP) common data model. EGEMS (Wash DC). 2014;2:1110.","journal-title":"EGEMS (Wash DC)"},{"key":"1223_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4258\/hir.2016.22.1.54","volume":"22","author":"D Yoon","year":"2016","unstructured":"Yoon D, Ahn EK, Park MY, Cho SY, Ryan P, Schuemie MJ, et al. Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res. 2016;22:54\u201358.","journal-title":"Healthc Inform Res"},{"key":"1223_CR21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995\u20131003.","journal-title":"Lancet"},{"key":"1223_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201\u20137.","journal-title":"Lancet"},{"key":"1223_CR23","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","volume":"372","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174\u201383.","journal-title":"Lancet"},{"key":"1223_CR24","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"ONTARGET Investigators","year":"2008","unstructured":"ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547\u201359.","journal-title":"N Engl J Med"},{"key":"1223_CR25","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1210\/en.2008-0502","volume":"150","author":"T Tagami","year":"2009","unstructured":"Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, et al. A selective peroxisome proliferator-activated receptor-\u03b3 modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology. 2009;150:862\u201370.","journal-title":"Endocrinology"},{"key":"1223_CR26","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.2337\/diabetes.54.12.3442","volume":"54","author":"M Schupp","year":"2005","unstructured":"Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor \u03b3 modulators with angiotensin receptor blocking activity. Diabetes. 2005;54:3442\u201352.","journal-title":"Diabetes"},{"key":"1223_CR27","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1161\/01.HYP.0000125142.41703.64","volume":"43","author":"T Shiuchi","year":"2004","unstructured":"Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension. 2004;43:1003\u201310.","journal-title":"Hypertension"},{"key":"1223_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/sj.jhh.1000434","volume":"11","author":"G Paolisso","year":"1997","unstructured":"Paolisso G, Tagliamonte MR, Gambardella A, Manzella D, Gualdiero P, Varricchio G, et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens. 1997;11:307\u201312.","journal-title":"J Hum Hypertens"},{"issue":"5 Suppl 1","key":"1223_CR29","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/j.amjmed.2006.01.011","volume":"119","author":"TW Kurtz","year":"2006","unstructured":"Kurtz TW. New treatment strategies for patients with hypertension and insulin resistance. Am J Med. 2006;119(5 Suppl 1):S24\u2013S30.","journal-title":"Am J Med"},{"key":"1223_CR30","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(21)01920-6","volume":"398","author":"M Nazarzadeh","year":"2021","unstructured":"Nazarzadeh M, Bidel Z, Canoy D, Copland E, Wamil M, Majert J, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet. 2021;398:1803\u201310.","journal-title":"Lancet"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01223-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01223-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01223-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:27:07Z","timestamp":1789378027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01223-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":30,"alternative-id":["1223"],"URL":"https:\/\/doi.org\/10.1038\/s41371-026-01223-9","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest related to this work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the Ethics Committee of Kangdong Sacred Heart Hospital. The other 16 hospitals participating are affiliated with the Research Border Free Zone of the Korea CDM data network, which acknowledges the IRB approval from the research organizing center and exempts individual IRB approval. Written informed consent was waived by the IRB, and the research adhered to the principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}